Earnings release
Page 1
EX - 99.1 2 exhibit991q22021earningspr.htm EX - 99.1 E OFEM BIOSCIENCE SⓇ Exhibit 99.1 Evofem Biosciences Reports Second Quarter 2021 Financial Results and Provides Corporate Update -- · 68 % increase in net product sales Q1 to Q2 -- -- 47 % increase in Phexxi prescriptions -- -- 65 % increase in dispensed units -- -- 52 % increase in Phexxi prescriber base -- -- Conference call scheduled for 4:30 p.m. ET today -- SAN DIEGO , August 11 , 2021 - Evofem Biosciences , Inc. , ( NASDAQ : EVFM ) ( “ Evofem " or the " Company " ) , today reported financial results for the three- and six - month periods ended June 30 , 2021 . " We are pleased to show strong and sustainable growth in Phexxi prescriptions and dispensed units in the second quarter . This momentum allows us to further accelerate the growth trajectory with our celebrity campaign launching in early September , ” said Saundra Pelletier , Evofem's Chief Executive Officer . Second quarter and recent highlights include : • • • • 12,763 PhexxiⓇ ( lactic acid , citric acid and potassium bitartrate ) prescriptions were filled and 14,810 units were dispensed to patients during the second quarter of 2021 , an increase of 47 % and 65 % , respectively , compared to the first quarter of 2021 . 61 % growth in the prescriber base in the second quarter of 2021 compared to the first quarter of 2021 , and over 7,700 healthcare providers have prescribed Phexxi from launch through mid - July . National brand ambassador campaign featuring an Emmy Award - winning celebrity launching in September 2021 to accelerate growth in Phexxi brand awareness and prescriptions . On track to complete enrollment in EVOGUARD by year - end 2021. This pivotal Phase 3 clinical trial is evaluating safety and efficacy of EVO100 for the prevention of chlamydia and gonorrhea in women . Financial Results For the three months ended June 30 , 2021 , Phexxi net product sales increased 68 % to $ 1.9 million , compared to $ 1.1 million in the three months ended March 31 , 2021. There were no net product sales in the second quarter of 2020 , since Phexxi was launched in the U.S. in September 2020 .